FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232605079> ?p ?o ?g. }

• W4232605079 endingPage "362" @default.
• W4232605079 startingPage "362" @default.
• W4232605079 abstract "362 Background: Most pts with mGEA do not respond to ICI or ramucirumab/paclitaxel (RAM/TAX). Emerging data suggest that ICI may potentiate subsequent therapy (Tx). In KN059 we unexpectedly observed durable responses in 2 pts on RAM/TAX after ICI (PMID 29674442). We examined if ICI impacts efficacy of subsequent RAM/TAX in a larger cohort and explored alterations in the tumor microenvironment. Methods: All pts with mGEA at Mayo Clinic (MN, AZ, FL) who received RAM/TAX (2014-19) were included. We compared best objective response rate (ORR: complete [CR] or partial response [PR]) per RECIST1.1 and overall survival (OS) in pts who received RAM/TAX with (Group A) vs without (Group B) immediately preceding PD-1 blockade. Chi square and multivariate logistic and Cox regression were used. We adjusted for total lines of Tx received and the line of Tx in which RAM/TAX was given, to control for potential differences in the biology of heavily treated pts or those receiving RAM/TAX as 2nd vs 3rd line Tx. We also adjusted for age and ECOG PS. Results: In total 87 pts met inclusion criteria. In the 19 pts (Group A) who received RAM/TAX (usually as 3rd line Tx) after progression on ICI, there was a 77% relative risk reduction of death after initiation of RAM/TAX compared to the 68 pts (Group B) who received RAM/TAX (usually as 2nd line) without preceding ICI (median OS 15.0 vs 7.6 mo; HR 0.23; P < .001). The ORR was also significantly higher (58% vs 18%; P < .001) including the CR rate (16% vs 1%; P = .006). Two CRs in Group A are ongoing (10 - 34 mo). Of note, 95% of Group A pts did not respond to ICI, and all had irRECIST progression on ICI. Immunofluorescent analysis from a responder showed 65-fold reduction (post vs pre-Tx) in intratumoral density of immunosuppressive FOXP3+ Tregs, with preserved density of antitumor CD8+ T cells. Conclusions: Higher than expected efficacy was observed on RAM/TAX when immediately preceded by ICI, suggesting ICI may enhance efficacy of subsequent anti-VEGFR/taxane therapy. This serial immunotherapy combination may be a novel option for pts with primary resistance to ICI and will be tested prospectively in a new randomized phase 2 trial (NCT04069273)." @default.
• W4232605079 created "2022-05-12" @default.
• W4232605079 creator A5002341560 @default.
• W4232605079 creator A5017792432 @default.
• W4232605079 creator A5031777309 @default.
• W4232605079 creator A5038413156 @default.
• W4232605079 creator A5045186065 @default.
• W4232605079 creator A5046724542 @default.
• W4232605079 creator A5050989157 @default.
• W4232605079 creator A5054238636 @default.
• W4232605079 creator A5059366804 @default.
• W4232605079 creator A5069036162 @default.
• W4232605079 creator A5077416215 @default.
• W4232605079 creator A5078997248 @default.
• W4232605079 creator A5082265798 @default.
• W4232605079 creator A5084698652 @default.
• W4232605079 date "2020-02-01" @default.
• W4232605079 modified "2023-09-27" @default.
• W4232605079 title "Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA)." @default.
• W4232605079 doi "https://doi.org/10.1200/jco.2020.38.4_suppl.362" @default.
• W4232605079 hasPublicationYear "2020" @default.
• W4232605079 type Work @default.
• W4232605079 citedByCount "0" @default.
• W4232605079 crossrefType "journal-article" @default.
• W4232605079 hasAuthorship W4232605079A5002341560 @default.
• W4232605079 hasAuthorship W4232605079A5017792432 @default.
• W4232605079 hasAuthorship W4232605079A5031777309 @default.
• W4232605079 hasAuthorship W4232605079A5038413156 @default.
• W4232605079 hasAuthorship W4232605079A5045186065 @default.
• W4232605079 hasAuthorship W4232605079A5046724542 @default.
• W4232605079 hasAuthorship W4232605079A5050989157 @default.
• W4232605079 hasAuthorship W4232605079A5054238636 @default.
• W4232605079 hasAuthorship W4232605079A5059366804 @default.
• W4232605079 hasAuthorship W4232605079A5069036162 @default.
• W4232605079 hasAuthorship W4232605079A5077416215 @default.
• W4232605079 hasAuthorship W4232605079A5078997248 @default.
• W4232605079 hasAuthorship W4232605079A5082265798 @default.
• W4232605079 hasAuthorship W4232605079A5084698652 @default.
• W4232605079 hasConcept C121608353 @default.
• W4232605079 hasConcept C126322002 @default.
• W4232605079 hasConcept C143998085 @default.
• W4232605079 hasConcept C2777511904 @default.
• W4232605079 hasConcept C530470458 @default.
• W4232605079 hasConcept C71924100 @default.
• W4232605079 hasConcept C90924648 @default.
• W4232605079 hasConceptScore W4232605079C121608353 @default.
• W4232605079 hasConceptScore W4232605079C126322002 @default.
• W4232605079 hasConceptScore W4232605079C143998085 @default.
• W4232605079 hasConceptScore W4232605079C2777511904 @default.
• W4232605079 hasConceptScore W4232605079C530470458 @default.
• W4232605079 hasConceptScore W4232605079C71924100 @default.
• W4232605079 hasConceptScore W4232605079C90924648 @default.
• W4232605079 hasIssue "4_suppl" @default.
• W4232605079 hasLocation W42326050791 @default.
• W4232605079 hasOpenAccess W4232605079 @default.
• W4232605079 hasPrimaryLocation W42326050791 @default.
• W4232605079 hasRelatedWork W10233532 @default.
• W4232605079 hasRelatedWork W12927781 @default.
• W4232605079 hasRelatedWork W14333088 @default.
• W4232605079 hasRelatedWork W1756981 @default.
• W4232605079 hasRelatedWork W18425634 @default.
• W4232605079 hasRelatedWork W19355547 @default.
• W4232605079 hasRelatedWork W2544042 @default.
• W4232605079 hasRelatedWork W5091422 @default.
• W4232605079 hasRelatedWork W7849647 @default.
• W4232605079 hasRelatedWork W8188359 @default.
• W4232605079 hasVolume "38" @default.
• W4232605079 isParatext "false" @default.
• W4232605079 isRetracted "false" @default.
• W4232605079 workType "article" @default.